David A. Siegel Infinity Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.14 - $0.24 $84 - $144	600 Added 1.03%	58,900 $12,000
Q1 2023 May 15, 2023	SELL	$0.16 - $0.74 $11,776 - $54,464	-73,600 Reduced 55.8%	58,300 $9,000
Q4 2022 Feb 14, 2023	SELL	$0.46 - $1.21 $88,642 - $233,167	-192,700 Reduced 59.37%	131,900 $73,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $92,335 - $266,050	-156,500 Reduced 32.53%	324,600 $386,000
Q2 2022 Aug 15, 2022	SELL	$0.49 - $1.2 $171,206 - $419,280	-349,400 Reduced 42.07%	481,100 $304,000
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $189,550 - $535,200	-223,000 Reduced 21.17%	830,500 $947,000
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $1.19 Million - $2.15 Million	-639,700 Reduced 37.78%	1,053,500 $2.37 Million
Q3 2021 Nov 15, 2021	BUY	$1.52 - $3.82 $802,256 - $2.02 Million	527,800 Added 45.29%	1,693,200 $5.79 Million
Q2 2021 Aug 16, 2021	BUY	$2.66 - $3.47 $1.04 Million - $1.36 Million	390,800 Added 50.45%	1,165,400 $3.49 Million
Q1 2021 May 17, 2021	BUY	$1.98 - $5.36 $1.1 Million - $2.97 Million	553,200 Added 249.86%	774,600 $2.5 Million
Q4 2020 Feb 16, 2021	BUY	$1.05 - $2.77 $232,470 - $613,278	221,400 New	221,400 $469,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.